Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/11662
Predictors of Response to Exclusive Enteral Nutrition in Newly Diagnosed Crohn ' s Disease in Children: PRESENCE Study from SEGHNP
Identifiers
DOI: 10.3390/nu12041012
eISSN: 2072-6643
WOS ID: 000531831300132
Scopus EID: 2-s2.0-85083254076
PMID: 32272604
Embase PUI: L2004153824
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordAuthor
Moriczi, Melinda; Pujol-Muncunill, Gemma; Martin-Masot, Rafael; Jimenez Trevino, Santiago; Segarra Canton, Oscar; Ochoa Sangrador, Carlos; Pena Quintana, Luis; Gonzalez Santana, Daniel; Rodriguez Martinez, Alejandro; Rosell Camps, Antonio
Publication date
2020-04Document type
research articleCitation
Moriczi M, Pujol-Muncunill G, Martin-Masot R, Jimenez Trevino S, Segarra Canton O, Ochoa Sangrador C, et al. Predictors of Response to Exclusive Enteral Nutrition in Newly Diagnosed Crohn ' s Disease in Children: PRESENCE Study from SEGHNP. Nutrients. 2020 Apr;12(4):1012.Abstract
Exclusive enteral nutrition (EEN) has been shown to be more effective than corticosteroids in achieving mucosal healing in children with Crohn ' s disease (CD) without the adverse effects of these drugs. The aims of this study were to determine the efficacy of EEN in terms of inducing clinical remission in children newly diagnosed with CD, to describe the predictive factors of response to EEN and the need for treatment with biological agents during the first 12 months of the disease. We conducted an observational retrospective multicentre study that included paediatric patients newly diagnosed with CD between 2014-2016 who underwent EEN. Two hundred and twenty-two patients (140 males) from 35 paediatric centres were included, with a mean age at diagnosis of 11.6 +/- 2.5 years. The median EEN duration was 8 weeks (IQR 6.6-8.5), and 184 of the patients (83%) achieved clinical remission (weighted paediatric Crohn's Disease activity index [wPCDAI] < 12.5). Faecal calprotectin (FC) levels (<mu>g/g) decreased significantly after EEN (830 [IQR 500-1800] to 256 [IQR 120-585] p < 0.0001). Patients with wPCDAI <less than or equal to> 57.5, FC < 500 <mu>g/g, CRP >15 mg/L and ileal involvement tended to respond better to EEN. EEN administered for 6-8 weeks is effective for inducing clinical remission. Due to the high response rate in our series, EEN should be used as the first-line therapy in luminal paediatric Crohn's disease regardless of the location of disease and disease activity.
Publisher version
https://dx.doi.org/10.3390/nu12041012Keywords
inflammatory bowel diseaseCrohn's disease
exclusive enteral nutrition
calprotectin
children
paediatric
MeSH
ChildMale
Female
Humans
Remission Induction
Adolescent
Crohn Disease
Enteral Nutrition
Retrospective Studies
DeCS
Inducción de RemisiónNutrición Enteral
Enfermedad de Crohn
Humanos
Femenino
Niño
Estudios Retrospectivos
Adolescente
Masculino